ERG Immunohistochemistry As an Endothelial Marker for Assessing Lymphovascular Invasion
Overview
Authors
Affiliations
Background: ERG, a member of the ETS family of transcription factors, is a highly specific endothelial marker. We investigated whether the use of ERG immunostaining can help pathologists detect lymphovascular invasion (LVI) and decrease interobserver variability in LVI diagnosis.
Methods: Fifteen cases of surgically resected colorectal cancers with hepatic metastasis were selected and the most representative sections for LVI detection were immunostained with ERG, CD31, and D2-40. Eight pathologists independently evaluated LVI status on hematoxylin and eosin (H&E) and the corresponding immunostained sections and then convened for a consensus meeting. The results were analyzed by kappa (κ) statistics.
Results: The average rate of LVI positivity was observed in 43% with H&E only, 10% with CD31, 29% with D2-40, and 16% with ERG. Agreement among pathologists was fair for H&E only (κ=0.27), D2-40 (κ=0.21), ERG (κ=0.23), and was moderate for CD31 (κ=0.55). Consensus revealed that ERG nuclear immunoreactivity showed better visual contrast of LVI detection than the other staining, with improved agreement and LVI detection rate (κ=0.65, LVI positivity rate 80%).
Conclusions: The present study demonstrated a superiority with ERG immunostaining and indicated that ERG is a promising panendothelial marker that might help pathologists increase LVI detection and decrease interobserver variability in LVI diagnosis.
Wang Z, Dayang E, Zwiers P, Hernandez Garcia M, Luxen M, van Meurs M Biomedicines. 2024; 12(8).
PMID: 39200137 PMC: 11351379. DOI: 10.3390/biomedicines12081672.
Cavallero S, Roustaei M, Satta S, Cho J, Phan H, In Baek K Sci Adv. 2024; 10(7):eadj7481.
PMID: 38354249 PMC: 10866565. DOI: 10.1126/sciadv.adj7481.
Chakraborty A, Kim A, Alabdullatif S, Campbell J, Alekseyev Y, Kaplan U Res Sq. 2024; .
PMID: 38343832 PMC: 10854286. DOI: 10.21203/rs.3.rs-3808970/v1.
The Usefulness of Elastin Staining to Detect Vascular Invasion in Cancer.
Gonzalez J, Bahmad H, Ocejo S, Abreu A, Popp M, Gogola S Int J Mol Sci. 2023; 24(20).
PMID: 37894944 PMC: 10607141. DOI: 10.3390/ijms242015264.
Wakid M, Almeida D, Aouabed Z, Rahimian R, Davoli M, Yerko V Brain Behav Immun Health. 2023; 34:100684.
PMID: 37822873 PMC: 10562768. DOI: 10.1016/j.bbih.2023.100684.